Belimumab Dosage

Medically reviewed by Drugs.com. Last updated on Mar 19, 2020.

• Overview
• Side Effects
• Dosage
• Professional
• Interactions
• More

Usual Adult Dose for Systemic Lupus Erythematosus

IV:
10 mg/kg IV over 1 hour at 2-week intervals for the first 3 doses and at 4-week intervals thereafter
SUBCUTANEOUS:
If transitioning from IV to subcutaneous administration, administer the first subcutaneous dose 1 to 4 weeks after the last IV dose: 200 mg subcutaneously once a week in the abdomen or thigh (preferably on the same day each week)

Comments:
-Consider premedication including an antihistamine, with or without an antipyretic, before the infusion.
-Subcutaneous dosing is not based on weight.

Use: Treatment of patients with active, autoantibody-positive, systemic lupus erythematosus (SLE) who are receiving standard therapy

Usual Pediatric Dose for Systemic Lupus Erythematosus

5 years and older:
10 mg/kg IV over 1 hour at 2-week intervals for the first 3 doses and at 4-week intervals thereafter

Comments:
-Subcutaneous dosing not been evaluated and is not approved for patients younger than 18 years.
-Consider premedication including an antihistamine, with or without an antipyretic, before the infusion.

Use: Treatment of patients 5 years and older with active, autoantibody-positive, systemic lupus erythematosus (SLE) who are receiving standard therapy

Renal Dose Adjustments

No adjustment recommended.

Liver Dose Adjustments

Data not available

Precautions

CONTRAINDICATIONS:
-Hypersensitivity to the active component or any of the ingredients

Safety and efficacy have not been established in patients younger than 5 years.
This drug is not recommended for use in children.

Consult WARNINGS section for additional precautions.

Dialysis

Data not available

Other Comments

Administration advice:
-Do not administer intravenous push or bolus.

Storage requirements:
-Refrigerate, protect from light.
-Do not freeze.
-The total time from reconstitution to completion of infusion should not exceed 8 hours.
-After reconstitution, if not used immediately, protect from direct sunlight, and refrigerate.
-After final dilution in sodium chloride 0.9% solution, may store refrigerated or at room temperature.

Reconstitution/preparation techniques: The manufacturer product information should be consulted.

IV compatibility:
-Not compatible with 5% glucose
-Do not infuse concomitantly in the same intravenous line with other agents.

General:
-The efficacy of this drug has not been evaluated in patients with severe active lupus nephritis or severe active central nervous system lupus; it has not been studied in combination with other biologics or IV cyclophosphamide.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer